US Stock Futures Signal Lower Start On Wall Street

Loading...
Loading...
Pre-open movers
US stock futures tumbled in early pre-market trade, ahead of the Chicago purchasing managers index. The Chicago PMI for September will be released at 9:45 a.m. ET, while the Dallas Fed general business activity index for September will be released at 10:30 a.m. ET. Futures for the Dow Jones Industrial Average tumbled 131 points to 15,064.00, while the Standard & Poor's 500 index futures fell 14.90 points to 1,671.50. Futures for the Nasdaq 100 index dropped 25.25 points to 3,197.75.
A Peek Into Global Markets
European markets were lower today, with the Spanish Ibex Index falling 1.19%, London's FTSE 100 index dropping 0.85% and STOXX Europe 600 Index declining 0.72%. German DAX 30 index fell 1.06% and French CAC 40 Index declined 1.19%. German retail sales rose 0.5% in August from July, versus economists' expectations for a 0.8% increase. Euro-zone inflation rate increased 1.1% y/y in September, versus a 1.3% rate in the previous month. Asian markets ended mostly lower today. Japan's Nikkei Stock Average fell 2.06%, China's Shanghai Composite climbed 0.68% and Australia's ASX/S&P500 dropped 1.60%. Hong Kong's Hang Seng index fell 1.50% and India's Sensex tumbled 1.76%. Japan's retail sales increased 1.1% y/y in August, while industrial output dropped 0.7% in August versus the earlier month. Japan's manufacturing PMI climbed to 52.5 in September, from 52.2 in August. The HSBC China Manufacturing PMI rose to a final reading of 50.2 in September, versus a reading of 50.1 in August.
Broker Recommendation
Analysts at Morgan Stanley downgraded Johnson Controls
JCI
from “overweight” to “underweight.” The target price for Johnson Controls has been lowered from $45 to $40. Johnson Controls shares closed at $42.53 on Friday.
Breaking news
  • DS Healthcare Group DSKX today announced it has signed an agreement with a distributor in China and will soon launch its products into the fast-growing Chinese beauty and personal care market. To read the full news, click here.
  • AMGEN AMGN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF). To read the full news, click here.
  • Sunshine Heart SSH today announced that it has launched a website dedicated to providing information to patients suffering from moderate to severe heart failure to learn about its C-Pulse U.S. pivotal trial, COUNTER HF™. To read the full news, click here.
  • 6fusion has signed a non-binding Letter of Intent (LOI) with CME Group CME to explore the development of an Infrastructure-as-a-Service (IaaS) Exchange. To read the full news, click here.
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Posted In: NewsEurozoneFuturesGlobalPre-Market OutlookMarketsMorgan StanleyUS Stock Futures
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...